March 3, 2026Open Access

Adjuvant aspirin and Cyclooxygenase-2 inhibitors in resected, PIK3CA-mutated colorectal cancer: A systematic review and meta-analysis of randomized controlled trials

Key Points

Disease-free survival improved with adjuvant NSAID therapy in patients with PIK3CA mutations, indicating potential benefits.
The use of NSAIDs showed variability in outcomes, yet overall benefits, especially in disease-free survival, are observed.
Systematic review and meta-analysis of randomized controlled trials were utilized to evaluate the impact of NSAIDs on survival metrics.
Confirmatory evidence is required to solidify the role of NSAIDs in treatment, emphasizing that results are still exploratory and benefits may vary.

Abstract

Adjuvant NSAID therapy is associated with improved DFS in patients with PIK3CA-mutated CRC. OS benefit remains uncertain, and findings from sensitivity analyses are exploratory. These findings support consideration of NSAIDs as a biomarker-informed adjuvant strategy in selected patients while underscoring the need for confirmatory evidence from ongoing randomized trials.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Blanchard-Cavagis et al. (Fri,) studied this question.

synapsesocial.com/papers/69a75f62c6e9836116a2ab9c https://doi.org/https://doi.org/10.1016/j.critrevonc.2026.105167

Bookmark

View Full Paper